PURPOSE
Lung adenocarcinomas (LUADs) harboring concurrent mutations in KRAS and STK11 define a clinically aggressive subgroup characterized by primary resistance to immune checkpoint inhibitors (ICIs). In contrast, KRAS/TP53 co-mutant tumors typically exhibit an inflamed tumor microenvironment (TME) and improved respon...
Carlos E. de Andrea, D. Ajona, C. Sainz et al.· Clinical Cancer Research· 0 citations
Humoral immune responses rely on germinal center (GC) reactions to generate long-lasting antibody responses with affinity maturation. CD137 (4-1BB) agonists are known to exert inhibitory effects on B-cell responses; however, the underlying mechanisms remain unclear. Here, we show that agonistic anti-CD137 monoclonal an...
Ana Martínez-Riaño, Raquel Cuesta, Dayanna Salinas et al.· EMBO Journal· 0 citations
Antibody-drug conjugates (ADCs) show clinical efficacy against several solid malignancies, inducing cytotoxic effects in malignant cells accompanied by changes in the composition of the tumor stroma. The therapeutic effects of some ADCs have been shown to be potentiated by combination with anti-PD(L)1 checkpoint inhibi...
Gabriel Gomis, Claudia Herrero, Saioa Arrieta-Aranzueque et al.· Cancer Research· 1 citation
Evidence is provided for a key role of TNFR1, as expressed by malignant cells, in orchestrating a pro-tumor immunosuppressive environment through secondary inflammatory mediators through secondary inflammatory mediators.
Elixabet Bolaños, Lorena Cañas-Zabala, Irene Olivera et al.· Journal of Experimental Medi...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.